Avanza Fonder AB Boosts Holdings in Kenvue Inc. $KVUE

Avanza Fonder AB grew its position in Kenvue Inc. (NYSE:KVUE) by 22.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 275,241 shares of the company’s stock after purchasing an additional 50,246 shares during the quarter. Avanza Fonder AB’s holdings in Kenvue were worth $4,748,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Salomon & Ludwin LLC purchased a new stake in shares of Kenvue during the 3rd quarter valued at $25,000. NBT Bank N A NY boosted its position in shares of Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after purchasing an additional 1,006 shares in the last quarter. Cornerstone Planning Group LLC grew its stake in Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares during the last quarter. Golden State Wealth Management LLC grew its stake in Kenvue by 150.1% during the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after buying an additional 1,190 shares during the last quarter. Finally, Trust Co. of Vermont increased its position in Kenvue by 50.9% during the 3rd quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock valued at $39,000 after buying an additional 804 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of KVUE opened at $17.53 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96. The stock has a 50-day moving average of $17.99 and a two-hundred day moving average of $17.14. The stock has a market cap of $33.59 billion, a P/E ratio of 22.76, a P/E/G ratio of 4.00 and a beta of 0.51. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. During the same period in the prior year, the company earned $0.26 earnings per share. The company’s revenue was up 3.2% on a year-over-year basis. As a group, research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were issued a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.7%. The ex-dividend date was Wednesday, February 11th. Kenvue’s dividend payout ratio is 107.79%.

Wall Street Analyst Weigh In

A number of research firms have commented on KVUE. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Barclays upped their price objective on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Friday, March 6th. Argus raised shares of Kenvue to a “hold” rating in a research report on Friday, March 6th. Canaccord Genuity Group lifted their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Finally, Citigroup boosted their target price on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 18th. Three equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average target price of $19.58.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.